A new study finds that the high burden of typhoid fever in sub-Saharan African countries calls for stronger prevention strategies, including the use and implementation of typhoid conjugate vaccines. The study estimates that there are 12.5 to 16.3 million cases of typhoid every year with 140,000 deaths.
Bio-TCV, a typhoid conjugate vaccine developed by IVI and Bio Farma, has been licensed in Indonesia following marketing approval from BPOM. The vaccine is expected to provide protection against typhoid fever as early as 9 months of age.
The International Vaccine Institute (IVI) has started clinical development of DuoChol, a new oral cholera vaccine in capsule form. This innovation offers improved thermostability, reducing storage challenges, while making vaccines more accessible to those who need them most.
A global study aims to better understand the burden of Human papillomavirus (HPV) among girls and women in low- and lower middle-income countries. The study will inform effective strategies to prevent infection and introduce HPV vaccine into national programs, protecting the health of girls and women and reducing rates of cervical cancer.
A global Phase 2/3 clinical trial found that vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members. The study showed a significant reduction in symptomatic cases among vaccinated household contacts and indicated that vaccines can play an important role in controlling future outbreaks.
Biovac has concluded a licensing agreement with the International Vaccine Institute (IVI) to manufacture an oral cholera vaccine, addressing the critical shortage of vaccines needed to prevent cholera globally. The partnership aims to increase production volumes, reduce supply gaps, and support Africa's indigenous vaccine industry.
The International Vaccine Institute (IVI) has launched a two-week training course for biologics development and manufacturing, targeting low- and middle-income countries. The program aims to enhance local production of vaccines and biologics in LMICs to address vaccine inequity and global pandemic preparedness.
Two projects aim to vaccinate 40,000 and 60,000 people in Ethiopia against cholera, using the OCV vaccine developed by IVI. The mass vaccination campaign will also establish a disease monitoring system to strengthen local public health capabilities.
A Phase II trial will investigate a prime-boost regimen using two different COVID-19 vaccines, with the goal of expanding access to vaccines in Africa. The study aims to demonstrate the safety and efficacy of a mixed schedule of COVID-19 vaccines.
The International Vaccine Institute (IVI) has initiated a Phase II/III clinical trial for the Bharat Biotech Chikungunya vaccine candidate BBV87, evaluating its safety and immunogenicity in healthy adults across five countries. The study aims to develop an affordable vaccine with the aim of achieving WHO prequalification.
SK bioscience's GBP510 vaccine candidate has shown promising safety and immunogenic response in Phase I/II clinical trials. IVI will partner with SK on global Phase III trials to accelerate development and WHO approval of the vaccine.
The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with the International Vaccine Institute (IVI) to conduct clinical trials of Sinopharm's BBIBP-CorV vaccine in African populations. The ECOVA programme aims to generate data on vaccine efficacy and safety against variants of concern, enabling expanded access to va...
The webinar, 'Evidence to Action: Advancing the Antimicrobial Resistance Agenda during a Pandemic', brings together global experts to share strategic reflections and insights on national prevention/control policies against antimicrobial resistance (AMR). Key findings include the urgent need for transparent, coordinated action across co...
Joint projects to fight cholera include vaccination for 540,000 people in Nepal and 250,000 in Mozambique. Enhanced surveillance capacity will also be strengthened.
A new study confirms the safety and immunogenicity of the Vi-DT conjugate vaccine in children aged 6-23 months. The single-dose regimen shows anti-Vi seroconversion rates similar to the two-dose schedule, offering a promising solution for increasing global vaccination stockpiles.
The International Vaccine Institute (IVI) is preparing clinical trial sites for COVID-19 vaccine efficacy trials in four African and Asian countries with the support of the Bill & Melinda Gates Foundation. IVI aims to bolster in-country capacity by 4Q2020 to ensure these sites are prepared for efficacy trials.
A new partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial in Colombia, Panama, and Thailand to assess the safety and immunogenicity of the BBV87 vaccine candidate. The investment aims to accelerate the development of an effective Chikungunya vaccine for equitable access.
IVI will conduct epidemiological studies of COVID-19 in Madagascar and Burkina Faso using its infectious disease surveillance sites. The collaboration aims to identify cases accurately and inform effective policies.
The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6.9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO's COVID-19 vaccine candidate based on their well-established DNA platform technology. The trial will be conducted in parallel to INOVIO's Phase I INO-4800 study underway in the US.
The International Vaccine Institute (IVI) and Technical University of Denmark (DTU) are strengthening external quality assurance programs in Asia to address the growing challenge of antimicrobial resistance. Quality-assured data is essential for developing tailored strategies to prevent the spread of drug-resistant infections.
The International Vaccine Institute (IVI) has renewed its partnership with Sweden's Swedish International Cooperation Agency (Sida) to accelerate vaccine research and development for global health. The five-year partnership will focus on infectious diseases of global importance, including cholera, typhoid, and dengue.
The International Vaccine Institute (IVI) has received a $1.4 million grant from the Bill & Melinda Gates Foundation to develop international standards for oral cholera vaccine manufacturing. This will enable multiple manufacturers to produce low-cost vaccines, meeting global demand and ensuring uniform efficacy.
A clinical study published in The Lancet Infectious Diseases shows that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. This breakthrough finding has significant implications for vaccination strategies and cost-effectiveness in developing countries.
The International Vaccine Institute (IVI) has been granted two US patents on novel Shigella protein antigens and methods, paving the way for an effective and low-cost vaccine against bacillary dysentery. The vaccine has the potential to provide cross-protection across species and serotypes of Shigella.
Scientists at the International Vaccine Institute have discovered a sublingual vaccine that protects mice against various flu viruses, including H5 and H1. The vaccine induces immunity in the lungs and offers an alternative strategy to prevent influenza infection.
Shanchol, a new oral cholera vaccine developed by IVI, has been prequalified by the World Health Organization for use in developing countries. The vaccine is ready to be used in large-scale immunization programs and has been shown to be safe and protective against cholera for three years.
At least one dengue vaccine could be licensed within the next 4 years. Developing countries' national regulatory authorities (NRAs) have a crucial role in accelerating the licensure process when a new dengue vaccine becomes available.
A group of experts recommends creating an emergency stockpile of cholera vaccines to rapidly deploy in high-risk areas, stabilizing countries and preventing outbreaks. The US would face low costs, while the benefits could be enormous, particularly in refugee camps.
Scientists discovered that chicken antibodies from vaccinated hens can prevent H5N1 and H1N1 infections in mice, raising hope for an affordable and effective alternative to control influenza outbreaks.
A new study by IVI-NICED found that the Vi polysaccharide vaccine is highly effective in protecting young children against typhoid fever, with 80% protection rate in children under five years old. The vaccine also conferred substantial herd protection, reducing typhoid risk among unvaccinated neighbors by 44%.